AIDS

Cigna lowers price of some HIV medications

The deal will cap the monthly price some patients may pay for medications such as Atripla.

Merck adds heat to HCV competition

Merck adds heat to HCV competition

By

Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.

HIV/AIDS site makes healthcare reform personal

HIV/AIDS site makes healthcare reform personal

By

The Kaiser Family Foundation's just-launched website, funded by Gilead, addresses healthcare reform from a distinct perspective.

Pediatricians want greater condom access

The AAP says greater access and education are critical in curbing STIs.

New daily HIV med could put Atripla on the defensive

New daily HIV med could put Atripla on the defensive

By

The GSK-Pfizer-Shionogi daily HIV medication gets the regulatory all-clear. The approval could put BMS/Gilead's best-selling daily med Atripla on the defensive.

HIV messaging goes communal

HIV messaging goes communal

By

Messaging around HIV testing now mixes individual concerns with community protection. Recent efforts, like those of the CDC and Greater than AIDS, try to make getting tested an empowering act.

Business briefs: Pharma's ad spend, Baby sheds HIV status

Pharma pared back its ad spend in 2012, a baby born HIV-positive is virus-free two-and-a-half years later, and Boston Children's Hospital is making its own apps.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters